This drug-linker conjugate, DBM-C5-VC-PAB-MMAE, is designed for ADC synthesis, featuring a maleimide-based linker (DBM) for antibody conjugation and a cleavable valine-citrulline linker attached to the cytotoxic payload MMAE. It is a key reagent for constructing ADCs used in cancer research, enabling the study of targeted drug delivery in both in vitro and in vivo experimental models.